
Palatin Technologies (NASDAQ:PTN – Free Report) – Research analysts at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for Palatin Technologies in a report issued on Tuesday, November 17th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($1.72) for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Palatin Technologies’ current full-year earnings is ($3.24) per share.
Palatin Technologies (NASDAQ:PTN – Get Free Report) last announced its earnings results on Monday, September 28th. The company reported ($1.11) EPS for the quarter. The business had revenue of $0.30 million for the quarter. Palatin Technologies had a negative net margin of 63.54% and a negative return on equity of 115.00%.
Read Our Latest Research Report on PTN
Palatin Technologies Price Performance
Shares of Palatin Technologies stock opened at $4.58 on Thursday. The stock has a market capitalization of $8.15 million, a P/E ratio of -0.81 and a beta of 0.75. Palatin Technologies has a 1 year low of $4.51 and a 1 year high of $31.00.
Institutional Trading of Palatin Technologies
An institutional investor recently bought a new stake in Palatin Technologies stock. State Street Corp bought a new position in Palatin Technologies (NASDAQ:PTN – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 14,000 shares of the company’s stock, valued at approximately $124,000. State Street Corp owned approximately 0.79% of Palatin Technologies at the end of the most recent quarter. 11.50% of the stock is owned by institutional investors.
Palatin Technologies Company Profile
Palatin Technologies is a biopharmaceutical company that develops peptide-based medicines designed to act on specific receptors. Its research has focused primarily on the melanocortin system, which is involved in a range of biological functions and potential therapeutic applications. The company’s commercial product is Vyleesi (bremelanotide), an injectable prescription medicine approved in the United States to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Featured Articles
- Five stocks we like better than Palatin Technologies
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
